TRPM8 Agonists for Neurodegeneration

TRPM8 Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TRPM8 Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">WS-12</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Menthol</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Icilin</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>TRPM8 (Transient Receptor Potential Melastatin 8)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Ion channel agonist</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>155-450 Da (small molecules)</td>
</tr>
<tr>
<td class="label">**Blood-Brain Barrier Penetration</td>
<td>Variable (depends on lipophilicity)</td>
</tr>
<tr>
<td class="label">Key Agonists</td>
<td>Menthol, WS-12, Icilin, Eucalyptol</td>
</tr>
</table>

TRPM8 (Transient Receptor Potential Melastatin 8) is a cold-sensing ion channel also known as the menthol receptor. It belongs to the TRP (Transient Receptor Potential) family of cation channels and is activated by temperatures below 25°C and by cooling compounds such as menthol, eucalyptol, and icilin. While traditionally studied in pain and thermoregulation, emerging research suggests TRPM8 may play important roles in neuroprotection and could be a therapeutic target for neurodegenerative diseases. [@bode2021]

TRPM8 Biology

TRPM8 Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TRPM8 Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">WS-12</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Menthol</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Icilin</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>TRPM8 (Transient Receptor Potential Melastatin 8)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Ion channel agonist</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>155-450 Da (small molecules)</td>
</tr>
<tr>
<td class="label">**Blood-Brain Barrier Penetration</td>
<td>Variable (depends on lipophilicity)</td>
</tr>
<tr>
<td class="label">Key Agonists</td>
<td>Menthol, WS-12, Icilin, Eucalyptol</td>
</tr>
</table>

TRPM8 (Transient Receptor Potential Melastatin 8) is a cold-sensing ion channel also known as the menthol receptor. It belongs to the TRP (Transient Receptor Potential) family of cation channels and is activated by temperatures below 25°C and by cooling compounds such as menthol, eucalyptol, and icilin. While traditionally studied in pain and thermoregulation, emerging research suggests TRPM8 may play important roles in neuroprotection and could be a therapeutic target for neurodegenerative diseases. [@bode2021]

TRPM8 Biology

TRPM8 is a non-selective calcium-permeable cation channel encoded by the [TRPM8](/genes/trpm8) gene. The channel is expressed in:

• Dorsal root ganglion (DRG) sensory neurons
• Trigeminal ganglion neurons
• Certain brain regions including hippocampus and cortex
• Some non-neuronal tissues

• Cold temperatures (<25°C)
• Chemical agonists: menthol, eucalyptol, WS-12, icilin
• Voltage-dependent activation at cold temperatures

Mechanism of Action

TRPM8 agonists provide neuroprotection through multiple mechanisms:

Key Neuroprotective Mechanisms

Therapeutic Potential

Alzheimer's Disease

In AD models, TRPM8 activation has been shown to:

• Protect against amyloid-beta toxicity
• Improve calcium signaling in hippocampal neurons
• Reduce oxidative stress
• Promote autophagy

Parkinson's Disease

TRPM8 agonists may provide neuroprotection in PD through:

• Protection of dopaminergic neurons
• Modulation of microglial activation
• Reduction of oxidative stress

Other Neurodegenerative Conditions

• Amyotrophic Lateral Sclerosis (ALS)
• [Huntington's Disease](/diseases/huntingtons-disease)
• [Multiple Sclerosis](/diseases/multiple-sclerosis)

Clinical Development

TRPM8 agonists remain primarily in preclinical development for neurodegeneration. Several synthetic agonists have shown promise in animal models:

Drug Properties

Side Effects and Considerations

• Cold sensation/hypersensitivity
• Potential for desensitization with chronic use
• Species differences in channel pharmacology
• Limited CNS penetration for some compounds

References

Related Pages

• [Ion Channel Modulators](/therapeutics/ion-channel-modulators-neurodegeneration)
• [Calcium Channel Blockers](/therapeutics/calcium-channel-blockers-neurodegeneration)
• [Neuroprotection](/therapeutics/neuroprotection)
• [TRPM8 Gene](/genes/trpm8)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;